SCHEMBL7230998

SCHEMBL7230998

COc1ccc2c(=O)c3c(OC)c(OC)c(OC)c(OC)c3oc2c1OC

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAOA P21397 2/20 0.58
KDM4E B2RXH2 4/20 0.56
ALDH1A1 P00352 3/20 0.56
ABCB1 P08183 2/20 0.55
ABCG2 Q9UNQ0 2/20 0.55
MGAM O43451 3/20 0.49
CA12 O43570 1/20 0.49
CA1 P00915 1/20 0.49
CA2 P00918 1/20 0.49
CA7 P43166 1/20 0.49
CA9 Q16790 1/20 0.49
CA13 Q8N1Q1 1/20 0.49
CYP3A4 P08684 2/20 0.48
MAPT P10636 2/20 0.48
MEN1 O00255 1/20 0.48
HPGD P15428 1/20 0.48
MAPK1 P28482 1/20 0.48
KMT2A Q03164 1/20 0.48
HSD17B10 Q99714 1/20 0.48
CYP1A2 P05177 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7236286 0.83 MAOA (0.68) MAOAKDM4EALDH1A1ABCB1ABCG2
SCHEMBL7231294 0.81 MAOA (0.62) MAOAKDM4EALDH1A1MGAMCA12
SCHEMBL151282 0.79 MAOA (0.72) MAOAKDM4EALDH1A1MGAM
SCHEMBL29378228 0.76 CA12 (0.63) MAOAKDM4EALDH1A1MGAMCA12
SCHEMBL5135083 0.75 ABCG2 (0.65) KDM4EALDH1A1ABCB1ABCG2MGAM
SCHEMBL30668674 0.74 MAOA (1.00) MAOAKDM4EALDH1A1ABCB1ABCG2
SCHEMBL27225536 0.74 ALDH1A1 (0.59) MAOAKDM4EALDH1A1MGAMCA12
SCHEMBL132462 0.74 MAOA (1.00) MAOAKDM4EALDH1A1ABCB1ABCG2
SCHEMBL28334427 0.74 MGAM (0.70) MAOAKDM4EABCB1MGAMCYP3A4
SCHEMBL27876462 0.73 MAOA (0.60) MAOAKDM4EALDH1A1ABCG2CA12

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6613797-B2 New xanthone derivatives useful for treating protozoan diseases INTERLAB, INC. 2003-09-02 US disclosed
EP-0888052-A4 XANTHONE ANALOGS FOR THE TREATMENT OF INFECTIOUS DISEASES INTERLAB CORP (US) 2002-05-22 EP disclosed
US-20020055644-A1 Xanthone analogs for treating infectious diseases and complexation of heme and porphyrins INTERLAB, INC. 2002-05-09 US disclosed
WO-2001041773-A1 XANTHONE ANALOGS FOR TREATING INFECTIOUS DISEASES AND COMPLEXATION OF HEME AND PORPHYRINS INTERLAB, INC. (US) 2001-06-14 WO disclosed
US-5977077-A PARASITICIDES; ANTIPROTOZOA AGENT INTERLAB CORPORATION (US) 1999-11-02 US disclosed
EP-0888052-A1 XANTHONE ANALOGS FOR THE TREATMENT OF INFECTIOUS DISEASES INTERLAB CORPORATION (US) 1999-01-07 EP disclosed
WO-1997034482-A1 XANTHONE ANALOGS FOR THE TREATMENT OF INFECTIOUS DISEASES INTERLAB CORP. (US) 1997-09-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020055644-A1 Xanthone analogs for treating infectious diseases and complexation of heme and porphyrins XPA, XDH, HMOX1 MAOA 680/4885KDM4E 3343/4885ALDH1A1 4117/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.